合同研究、開發和生(sheng)(sheng)產(chan)(chan)(CRDMO)公司藥明(ming)生(sheng)(sheng)物(wu)(wu)(wu)(wu)宣布基于微生(sheng)(sheng)物(wu)(wu)(wu)(wu)發酵技術的生(sheng)(sheng)物(wu)(wu)(wu)(wu)藥原液十四廠(chang)(MFG14)已正(zheng)式獲得cGMP生(sheng)(sheng)產(chan)(chan)放行(xing)，并自今年初以來交付(fu)多(duo)個(ge)客戶的CMC項目。這也標志著(zhu)藥明(ming)生(sheng)(sheng)物(wu)(wu)(wu)(wu)從(cong)DNA到cGMP生(sheng)(sheng)產(chan)(chan)的一體化(hua)服務能力擴大至微生(sheng)(sheng)物(wu)(wu)(wu)(wu)發酵領(ling)域。(醫藥健聞)